Loading...
Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
BACKGROUND: We evaluated the impact of 3 months of mFOLFOX6 adjuvant chemotherapy or surgery alone in comparison with 6 months of mFOLFOX6 on disease-free survival (DFS) in deficient mismatch repair (dMMR) colon cancer (CC) patients. METHODS: This retrospective study identified a cohort of patients...
Na minha lista:
| Udgivet i: | Front Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7747753/ https://ncbi.nlm.nih.gov/pubmed/33344234 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.579478 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|